Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  12/7/2015
Clinical Research Facility
mi
from
Morgantown, WV
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 12/7/2015
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  12/7/2015
Clinical Research Facility
mi
from
Madison, WI
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 12/7/2015
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated:  12/7/2015
Research Site
mi
from
New Lambton Heights,
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Status: Enrolling
Updated: 12/7/2015
Research Site
mi
from
New Lambton Heights,
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Birmingham, AL
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Stanford, CA
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Denver, CO
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Washington,
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Gainsville, FL
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Gainsville, FL
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Miami, FL
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Tampa, FL
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Kansas City, KA
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Bethesda, MD
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Rochester, MN
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
New York, NY
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Cleveland, OH
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Portland, OR
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Charleston, SC
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Tyler, TX
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated:  12/8/2015
mi
from
Toronto,
Arikayce for Nontuberculous Mycobacteria
A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
Status: Enrolling
Updated: 12/8/2015
mi
from
Toronto,
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Arizona Pediatric Cardiology Consultants
mi
from
Phoenix, AZ
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Arizona Pediatric Cardiology Consultants
mi
from
Phoenix, AZ
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Indiana University
mi
from
Indianapolis, IN
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
University of Michigan
mi
from
Ann Arbor, MI
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Washington University
mi
from
St. Louis, MO
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Oklahoma University Health Sciences Center
mi
from
Oklahoma City, OK
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Oklahoma University Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Cardiothoracic and Vascular Surgeons and Austin Heart
mi
from
Austin, TX
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Cardiothoracic and Vascular Surgeons and Austin Heart
mi
from
Austin, TX
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Methodist Healthcare System of San Antonio
mi
from
San Antonio, TX
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Methodist Healthcare System of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated:  12/8/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
CryoValve SG Pulmonary Human Heart Valve Post Clearance Study
Status: Enrolling
Updated: 12/8/2015
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)
Evaluation of the Bronchoprotective Effect of Arformoterol in Children With Exercise Induced Bronchospasm
Status: Enrolling
Updated:  12/9/2015
University of New Mexico
mi
from
Albuquerque, NM
Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)
Evaluation of the Bronchoprotective Effect of Arformoterol in Children With Exercise Induced Bronchospasm
Status: Enrolling
Updated: 12/9/2015
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01040 Boehringer Ingelheim Investigational Site
mi
from
Stamford, CT
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01040 Boehringer Ingelheim Investigational Site
mi
from
Stamford, CT
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1275.1.01111 Boehringer Ingelheim Investigational Site
mi
from
Duluth, GA
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1218.61.01007 Boehringer Ingelheim Investigational Site
mi
from
Greensboro, NC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1218.61.01007 Boehringer Ingelheim Investigational Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01309 Boehringer Ingelheim Investigational Site
mi
from
Dayton, OH
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01309 Boehringer Ingelheim Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01287 Boehringer Ingelheim Investigational Site
mi
from
Toledo, OH
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01287 Boehringer Ingelheim Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1218.61.01031 Boehringer Ingelheim Investigational Site
mi
from
East Providence, RI
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1218.61.01031 Boehringer Ingelheim Investigational Site
mi
from
East Providence, RI
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01013 Boehringer Ingelheim Investigational Site
mi
from
Gaffney, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01013 Boehringer Ingelheim Investigational Site
mi
from
Gaffney, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.419.01056 Boehringer Ingelheim Investigational Site
mi
from
Union, SC
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.419.01056 Boehringer Ingelheim Investigational Site
mi
from
Union, SC
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
1222.51.01028 Boehringer Ingelheim Investigational Site
mi
from
Boerne, TX
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
1222.51.01028 Boehringer Ingelheim Investigational Site
mi
from
Boerne, TX
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials